Superior Vena Cava Syndrome from Percutaneous Right Ventricular Assist Device Use in Right Ventricular Failure

2020 ◽  
Vol 39 (4) ◽  
pp. S394
Author(s):  
B. Badu ◽  
Z. Laste ◽  
M. Cain ◽  
A. Mohammed ◽  
D. Joyce
2021 ◽  
Vol 3 (15) ◽  
pp. 1690-1693
Author(s):  
John R. Vaile ◽  
J. Eduardo Rame ◽  
Rene J. Alvarez ◽  
Howard T. Massey ◽  
Vakhtang Tchantchaleishvili ◽  
...  

2021 ◽  
Author(s):  
Matteo Trezzi ◽  
Gianluca Brancaccio ◽  
Sergio Filippelli ◽  
Claudia Esposito ◽  
Roberta Iacobelli ◽  
...  

2012 ◽  
Vol 23 (1) ◽  
pp. 86-90 ◽  
Author(s):  
Mark Puhlman

Left ventricular assist devices (LVADs) have become accepted as treatment for heart failure as a result of improvements in diagnosing and treating left ventricular failure and limited donor availability. In the Pivotal Study of the HeartMate II in the bridge to transplantation population, the incidence of right ventricular failure without the implantation of a right ventricular assist device was 14%, with an additional 6% of the participants ill enough that they required implantation of a right ventricular assist device. This complication increases mortality, cost, and length of stay. This article reviews the screening of LVAD candidates for the probability of right ventricular failure postoperatively, the evaluation of right ventricular function in LVAD candidates, and the optimal management of the right ventricle during the perioperative care of LVAD patients.


Sign in / Sign up

Export Citation Format

Share Document